[Congressional Record Volume 146, Number 112 (Wednesday, September 20, 2000)]
[Senate]
[Pages S8781-S8782]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]
MEDICARE REFORM
Mr. GRAHAM. Mr. President, for the past 3 days I have been discussing
the need to reform Medicare and the fundamental reform of shifting
Medicare from being a program that focuses on sickness and dealing with
disease and the consequences of accidents after they happen, to a
health care system that focuses on wellness and maintaining the highest
possible quality of life. I pointed out that an essential ingredient of
any wellness strategy is prescription drugs. Prescription drugs are a
modality in virtually every form of therapy which is designed to
reverse disease conditions or to manage those conditions.
Yesterday, I talked about the fact that the prescription drug benefit
for senior Americans should be provided through the Medicare program.
It is the program which the seniors themselves have indicated over and
over that they believe in, they trust, they have confidence in, and
that they would like it to be the program through which this additional
benefit would be added to all the other benefits that are available
through Medicare. They would also like prescription drugs to be
available through Medicare.
In the context of the discussion of our colleague from California, I
must point out that while the seniors are saying they want to have a
prescription drug benefit administered through Medicare, the Governors
of the States are saying they do not want to have the responsibility
for administering a prescription drug benefit; it is not our job nor
should it be our financial responsibility to be involved in
prescription drugs for a group of Americans who have since 1965 been
covered by a national program and not a State-by-State program.
I would like to talk about the issue of cost and which alternative
before us has the best opportunity to serve not only the interests of
the 39 million seniors but all Americans in terms of injecting some
control over an out-of-control, spiraling increase in the cost of
pharmaceutical drugs.
Let me use as an illustration what has happened to a constituent of
mine, Mrs. Elaine Kett. Mrs. Kett is a 77-year-old widow from Vero
Beach, FL. She lives on a fixed income of approximately $20,000 a year,
which means that her income is above the level that would provide
benefits for her under the kind of plan that my Teutonic cousin from
Texas has indicated he would support.
Like many of my constituents, Mrs. Kett sent me a list of all the
prescription drugs that her physician has indicated are medically
necessary for her wellness and quality of life. These are the lists of
Mrs. Elaine Kett's drugs. As you will see when you add up all the costs
of the drugs which she used in 1999, the total cost was $10,053.36.
Mrs. Kett has already said her income is $20,000 a year. Fifty cents
out of every dollar of Mrs. Kett's income was consumed in paying for
the prescription drugs necessary for her life, wellness, and quality.
In her letter, Mrs. Kett writes:
This is killing me because my income is just a bit more
than double the cost of these drugs.
Then she adds a postscript.
P.S.--Someone said these are the golden years, only the
gold is going into someone else's pocket.
There are millions of Americans just like Mrs. Kett. Passing a real
prescription drug benefit to cover Mrs. Kett and all Medicare
beneficiaries should be a priority for this session of the Congress.
Today, we will examine one of the key reasons why so many seniors are
unable to purchase the medications which their physicians have said are
medically necessary. The reason is cost.
Prescription drug prices are growing so quickly that seniors and, I
would argue, most Americans cannot keep up. In July, Families USA
released a report that concluded:
The growing reliance on prescription drugs by the elderly
and the mounting costs of those drugs is a crisis for
America's senior citizens.
[[Page S8782]]
The elderly already pay a significant portion of prescription drugs
expenditures out of their pockets. Today, many seniors are without any
prescription drug coverage.
The traditional ways in which seniors have been covered for
prescription drugs--which have included employers who provided those
benefits to their retirees through the Medicaid program if they were
medically indigent or through Medigap policies if they could afford the
often exorbitant costs, and through HMOs which provided prescription
drugs as a benefit--are constricting in terms of who they will cover
and what they will cover.
So every week, more seniors are placed in the position of either
having to cover their entire prescription drug costs or a larger
proportion of that cost.
Today, almost one out of three seniors lacks any prescription drug
coverage. Over 50 percent of Medicare beneficiaries lack coverage at
some point during any given year. For those fortunate enough to have
prescription drug coverage, the coverage is diminishing.
Thus, unless seniors are assured of prescription drug coverage
through Medicare, many will find that needed medications are
unavailable.
If it is true that the lack of prescription drug coverage has reached
a crisis level for seniors, then why have we not yet enacted a real,
affordable, and comprehensive prescription drug benefit under Medicare?
The answer, I suspect, includes the fact that the pharmaceutical
companies may have erected an effective blockade to the enactment of a
prescription drug benefit through Medicare.
In fact, the watchdog group, ``Public Citizen,'' reports that drug
companies spent $83.6 million in lobbying costs this year alone.
I would suspect from looking at the television ads run by the
industry that much of those moneys have been spent on lobbying efforts
against the passage of a universal, affordable Medicare prescription
drug benefit.
Why do the pharmaceutical companies cringe at a Medicare prescription
drug proposal? It is because they know the power of the marketplace. As
long as 39 million senior Americans have to deal, one by one, and as
long as almost one-third of those have to deal without any assistance
from any other source in the purchase of their prescription drugs, the
market will not function. There is no effective purchaser-seller
relationship.
What we do know is that when there is an effective market, prices can
be restrained. We know it through the Veterans' Administration, which
is able to purchase the exact same prescription drugs Mrs. Kett has
been purchasing, but at substantially lower prices because they are
using the power of a large purchaser for the benefit of American
veterans. State Medicaid programs know this because they are using the
power of their large purchases for the benefit of the million medically
indigent within their States. HMOs know the power of the marketplace
because they purchase their prescription drugs on a wholesale basis and
then share those benefits with HMO beneficiaries.
With or without the support of the pharmaceutical companies, we must
seek relief for seniors who are the victims of this crisis. The cost of
prescription drugs is skyrocketing. We owe it to our seniors to examine
the reasons and then to act.
In 1999, the prices of the 50 prescription drugs most used by older
Americans increased 2 to 3 times the rate of overall inflation. In 1
year, the 50 most used prescription drugs by American seniors increased
by 2 to 3 times the rate of overall inflation.
The numbers speak for themselves: Lorazepam, used to treat conditions
including anxiety, convulsions, and Parkinson's disease, rose by 409
percent, 27 times the rate of inflation, from January 1994 through
January 2000. Imdur, a drug used to treat angina, rose eight times the
rate of inflation. And Lanoxin, used to treat congestive heart failure,
rose at six times the rate of inflation.
Not only are the prices of drugs escalating at a rapid pace in the
United States, but prices charged to Americans are also flat out
incomprehensible.
We have all heard that prices of prescription drugs in other
countries--including our neighbors, Canada and Mexico--are generally
substantially lower than prices in the United States. The heartburn
medicine Prilosec, the world's best seller, the largest selling
prescription drug, costs $3.30 per pill in the United States. What is
the price in Canada? One dollar and forty-seven cents. The allergy drug
Claritin costs almost $2 a pill in the United States. What does it cost
elsewhere? Forty-one cents in Great Britain and 48 cents in Australia.
We are talking about exactly the same drug produced by the same
manufacturer.
A constituent from Springhill, FL, called my office yesterday
demanding to know why drug prices are so much lower in Mexico and
Canada than they are in his hometown. I can't answer that question.
Frankly, I don't think anyone can answer that question. Pharmaceutical
manufacturers have been the top-ranked U.S. industry for profits as a
percentage of revenue throughout the past decade. After-tax profits for
the pharmaceutical industry average 17 percent of sales. By way of
comparison, the average for all industries was 5 percent. The effective
tax rate for the pharmaceutical industry is 16 percent. The effective
tax rate for all manufacturing companies is 23 percent; 31 percent for
wholesale and retail trade, financial services, and insurance and real
estate, and an average of 27 percent for all industry.
While millions of seniors are sacrificing their last dollar, as is
Mrs. Kett, to pay for medication, the pharmaceutical manufacturers are
taking in higher profits than any other industry in the United States
of America.
Money does not take precedence over health. Profits cannot be the top
priority when public health is compromised. We have that responsibility
as the representative of those Americans to take action.
One of the things we ought to do in addition to adding prescription
drugs as a part of Medicaid is to assure public access to true drug
prices as opposed to the mythic average wholesale price. This would be
one step to encourage accountability among drug manufacturers. Rapidly
escalating prices and inequitable prices across borders warrant an
investigation and consideration of prescription drug costs containment.
I submit that by having Medicare as a new force in the marketplace,
not through regulation or cost control but by using the principles of
Adam Smith in a capitalist society, that with an effective purchaser of
drugs for our 39 million seniors, we can see a substantial reduction in
the price of pharmaceuticals for them, and all Americans will
indirectly benefit. As public servants, we have a fundamental
responsibility to protect all of our citizens.
We all recognize that millions of seniors in America are struggling
to pay for prescription drugs, so it seems clear our goal in the Senate
should be to assure that our prescription drug benefit for seniors and
people with disabilities is included in Medicare.
Our proposal is that Medicare would utilize an intermediary referred
to as a ``pharmacy benefit manager.'' There would be two or more of
these managers in each region of the country. They would be the ones
responsible for negotiating with the pharmaceutical companies and then
passing on those benefits to the ultimate senior user. We cannot
achieve these kinds of benefits through the fractured plan that relies
upon private insurance. We cannot assure these benefits by a plan which
is fractured through 50 States. We can only assure to our seniors the
benefits of effective control by the marketplace if we place this plan
within the Medicare program.
I appreciate the opportunity to share these remarks and look forward
to a further discussion of prescription drug prices that we face in
this Nation.
The PRESIDING OFFICER (Mr. Hutchinson). The Senator from North
Dakota.
____________________